Sin conexión a internet: se muestra la versión guardada de la página.

Iovance Biotherap…

USUSD
← Al Screener

Iovance Biotherapeutics Inc (LSE:0JDK) — Biotechnology: Biological Products (No Diagnostic Substances). Número de bolsas en las que cotizan las acciones de la empresa: 2. En esta página: cotización y gráfico, dividendos, principales accionistas e historial del número de acciones.

Sobre la Empresa

Sitio Web
iovance.com
Relaciones con los Inversores
ir.iovance.com/
Sector
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Sede Central
San Carlos, United States
Consejero Delegado
Frederick G. Vogt
Empleados
975
Fundada
2007
Acciones en Circulación
452.97 M a 2026-07-29
Capital Flotante
394.31 M
Capitalización Bursátil
6.71 mil M USD
Insiders
0.35%
Inversores Institucionales
70.68%
Industria (SIC)
Biological Products, (No Diagnostic Substances)
ISIN
US4622601007
LEI
2549002L8WT2ACU5Q878
P/E
pérdidas
FCF
−296 M USD
Deuda
1.00 M USD
caja neta
Resultados y FCF — para los 12 meses hasta 30.06.2026 (el último informe de la empresa).
NAV
1.62 USD · P/NAV 9.23
Fecha del Balance30.06.2026
Activos916 M USD
− Pasivos179 M USD
= NAV (patrimonio de los accionistas de la empresa)736 M USD
− Activos Intangibles264 M USD
= NAV Tangible472 M USD
Acciones452 971 016
NAV por Acción1.62 USD
NAV Tangible por Acción1.04 USD
Precio de la Acción (0JDK)14.9900 USD
P/NAV9.23
Historial del NAV
Fecha del BalanceNAVNAV por Acción
30.06.2026736 M USD1.62 USD
31.03.2026722 M USD1.65 USD
31.12.2025699 M USD1.70 USD
30.09.2025702 M USD1.82 USD
30.06.2025698 M USD2.04 USD
31.03.2025768 M USD2.30 USD
31.12.2024710 M USD2.33 USD
30.09.2024773 M USD2.54 USD
Descripción

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

anuncio

Bolsas y Tickers

BolsaTickerMonedaPrecioTipo
US USA StocksIOVA principalUSD14.62 -1.62%acciones ordinarias
LSE London Stock Exchange0JDK IOBUSD14.99 +0.00%acciones ordinarias

Precio en 3 Meses

día alcista día bajistaPasa el cursor / toca un día — precios de apertura, cierre, máximo y mínimo

Principales Accionistas

TitularParticipaciónAccionesFecha del Informe
Blackrock Inc.8.16%36.96 M2026-06-30
MHR Fund Management, LLC6.39%28.97 M2026-06-30
State Street Corporation5.4%24.48 M2026-06-30
Two Sigma Investments, L…4.2%19.01 M2026-06-30
Vanguard Capital Managem…4.02%18.2 M2026-06-30
SPDR SERIES TRUST-State…3.38%15.3 M2026-08-31
Vanguard Portfolio Manag…3.18%14.39 M2026-06-30
VANGUARD INDEX FUNDS-Van…2.98%13.49 M2026-06-30
Geode Capital Management…2.28%10.32 M2026-06-30
iShares Trust-iShares Ru…2.25%10.2 M2026-08-31
Millennium Management Ll…1.88%8.53 M2026-06-30
Dimensional Fund Advisor…1.43%6.46 M2026-06-30
Palo Alto Investors Lp1.17%5.3 M2026-06-30
VANGUARD INDEX FUNDS-Van…1.07%4.86 M2026-06-30
Fidelity Salem Street Tr…0.96%4.35 M2026-07-31
VANGUARD INDEX FUNDS-Van…0.95%4.31 M2026-06-30
iShares Trust-iShares Ru…0.82%3.71 M2026-08-31
VANGUARD INDEX FUNDS-Van…0.68%3.08 M2026-06-30
iShares Trust-iShares Bi…0.64%2.9 M2026-08-31
TIAA-CREF Funds-Nuveen Q…0.6%2.71 M2026-07-31
VOGT FREDERICK G (Chief…≈0.13%595 4472026-09-08
PURI RAJ K (Officer)≈0.06%256 3642026-09-08
KIRBY DANIEL GORDON (Off…≈0.03%154 5112026-08-10
BILINSKY IGOR P (Chief O…≈0.03%142 0742026-09-08
GRAF FINCKENSTEIN FRIEDR…≈0.03%140 1112026-06-05
BELLEMIN JEAN-MARC (Chie…≈0.01%60 5292025-06-02
ROCHE CORLEEN M (Chief F…≈0.01%28 7572026-08-06
MAYNARD RYAN D (Director…≈0%7 5002024-11-12